

AMENDMENTS TO THE CLAIMS

Claims 1-25 (canceled).

Claim 26 (currently amended) A method of producing activated T cells directed towards stratum corneum chymotryptic enzyme (SCCE), comprising the steps of:

exposing dendritic cells to a human SCCE peptide ~~polypeptide~~ ~~consisting of an amino acid sequence~~ selected from the group consisting of SEQ ID NOs: ~~[[Nos.]]~~ 31, 32, 33, 34, 35, 36, 80, 86, 99 ~~and amino acid sequence or the~~ human SCCE protein encoded by the DNA of SEQ ID NO: ~~[[No.]]~~ 30, thereby producing activated dendritic cells; and

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said SCCE peptide ~~polypeptide~~ to said T cells, thereby producing activated T cells directed toward said SCCE ~~polypeptide~~.

Claims 27-29 (canceled).

Claim 30 (previously presented) The method of claim 26, wherein said dendritic cells are isolated from an individual prior to said exposure to said SCCE polypeptide, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure.

Claim 31 (currently amended) The method of claim 30, wherein said individual has ovarian cancer, ~~[[or]]~~ prostate cancer, breast cancer or colon cancer ~~or is at risk for ovarian cancer or prostate cancer~~.

Claim 32-39 (canceled).